GlassScriptPhysician profile
Aurash Bina
NPI 1174089379
$7,244.47
in general payments reported to CMS, 2019-2025
23 companies · $3,381 in 2025
The $3,381 reported for 2025 was more than what 86% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $44.32 · 2021: $166 · 2022: $320 · 2023: $1,075 · 2024: $2,258 · 2025: $3,381.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,635 · Education: $80.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,634.70 |
| Education | $80.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,396.14 | 2023-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $868.56 | 2024-2025 | Tremfya |
| Lilly USA, LLC | $775.92 | 2020-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $568.59 | 2023-2025 | Ilumya, Winlevi |
| Incyte Corporation | $532.61 | 2023-2025 | Opzelura, Opzelura |
| Pfizer INC. | $485.85 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $350.72 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $267.49 | 2023-2025 | Aklief, Nemluvio, Twyneo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $258.06 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Novartis Pharmaceuticals Corporation | $257.92 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $241.85 | 2024-2025 | Dupixent, Libtayo |
| Mayne Pharma Commercial LLC | $195.26 | 2024-2025 | |
| Genzyme Corporation | $183.27 | 2024-2025 | |
| Dermavant Sciences, INC. | $175.61 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.59 | 2023-2024 | Spevigo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $166.32 | 2023-2025 | Bimzelx |
| Amgen INC. | $82.07 | 2023-2024 | Otezla |
| Organon LLC | $79.71 | 2025 | Vtama |
| Leo Pharma INC. | $59.92 | 2024-2025 | Anzupgo, Adbry |
| E.R. Squibb & Sons, L.L.C. | $48.69 | 2024 | Sotyktu |
| Botanix Sb INC | $31.78 | 2025 | Sofdra |
| Almirall LLC | $28.18 | 2025 | Seysara |
| Lnhc, INC | $23.36 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurash Bina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.